{"ticker": {"uuid": "c1ca7e40-be3f-43b6-9b3b-a4904065c0dd", "symbol": "GTBP", "name": "GT Biopharma Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "GT Biopharma (GTBP) Revenue Breakdown - Main Composition", "summary": "The article \"GT Biopharma (GTBP) Revenue Breakdown - Main Composition\" is a placeholder document that suggests it's intended to detail the revenue composition of GT Biopharma. However, it currently contains no substantive content, indicating it is an empty or unwritten document.", "url": "https://www.moomoo.com/stock/GTBP-US/financials-revenue?chain_id=Name1K9-3FXPhg.1kvvik0&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A64,%22f%22%3A%22www.moomoo.com%2Fcommunity%2Fprofile%2F152378380%22%7D", "source_name": "Moomoo", "published_at": "2026-07-07T03:39:29", "published_display": "07 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma (GTBP) plans reverse stock split and larger 2022 incentive plan", "summary": "GT Biopharma (GTBP) is proposing a reverse stock split, ranging from 1-for-10 to 1-for-30, along with a reduction in authorized common and preferred shares, to regain compliance with Nasdaq's minimum bid price requirement. The company is also seeking stockholder approval to incre", "url": "https://www.stocktitan.net/sec-filings/GTBP/def-14a-gt-biopharma-inc-definitive-proxy-statement-924a06788fca.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:39:40", "published_display": "02 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of GT Biopharma, Inc. \u2013 NASDAQ:GTBP", "summary": "This article provides an overview of the Enterprise Value to EBITDA forward for GT Biopharma, Inc. (NASDAQ: GTBP). It lists the company's stock market information and indicates that no trades have occurred, with the market appearing closed. The content is primarily a data placeho", "url": "https://www.tradingview.com/symbols/NASDAQ-GTBP/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T13:14:05", "published_display": "01 Jul 2026 13:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of GT Biopharma Inc \u2013 MUN:OXIA", "summary": "This article provides financial information for GT Biopharma Inc (MUN:OXIA) on TradingView, specifically focusing on the enterprise value to EBITDA forward metric. The content, while primarily navigational and descriptive of the TradingView platform, indicates that the market was", "url": "https://www.tradingview.com/symbols/MUN-OXIA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T04:39:16", "published_display": "30 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of GT Biopharma Inc \u2013 FWB:OXIA", "summary": "This article provides financial data for GT Biopharma Inc (FWB:OXIA) on the Frankfurt Stock Exchange. It specifically highlights the \"Price to book forward\" metric, displayed within a seemingly data-driven interface provided by TradingView. The page indicates that the market is c", "url": "https://www.tradingview.com/symbols/FWB-OXIA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T03:10:11", "published_display": "29 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of GT Biopharma Inc \u2013 FWB:OXIA", "summary": "This article focuses on the \"Enterprise value to revenue forward\" metric for GT Biopharma Inc (FWB:OXIA) on the Frankfurt Stock Exchange, as presented on TradingView. It appears to be a financial data point without further analysis or detailed content presented in the provided te", "url": "https://www.tradingview.com/symbols/FWB-OXIA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T20:40:31", "published_display": "28 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of GT Biopharma, Inc. \u2013 NASDAQ:GTBP", "summary": "This article provides financial data for GT Biopharma, Inc. (NASDAQ: GTBP), specifically focusing on its enterprise value to EBIT forward. It indicates that the market is currently closed, and no trades have occurred for the stock.", "url": "https://www.tradingview.com/symbols/NASDAQ-GTBP/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T18:40:31", "published_display": "28 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Inc Actuals & Estimates (SWB:OXIA)", "summary": "This article provides an overview of GT Biopharma Inc (SWB:OXIA) financials and analyst estimates. It highlights key financial data such as earnings per share and revenue, upcoming earnings dates, and analyst price targets. The company's last reported earnings were -0.10 EUR per ", "url": "https://www.tradingview.com/symbols/SWB-OXIA/forecast-actuals-and-estimates/?category=income_statement", "source_name": "TradingView", "published_at": "2026-06-27T07:40:08", "published_display": "27 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Inc (GTBP) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for GT Biopharma Inc (GTBP), noting its current risk assessment score of 1.27 and ranking within the Biotechnology & Medical Research industry. It details the company's beta value of 0.79, indicating it tends to underperform during upward m", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gtbp/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-27T05:11:21", "published_display": "27 Jun 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Inc Actuals & Estimates (NASDAQ:GTBP)", "summary": "This article provides an overview of GT Biopharma, Inc. (NASDAQ: GTBP) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the stock's recent decline, an analyst price target of USD 3.00, and upcoming earnings report sc", "url": "https://www.tradingview.com/symbols/NASDAQ-GTBP/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T16:10:59", "published_display": "25 Jun 2026 16:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Inc (GTBP) Valuation: PE, PB & Fair Value Analysis", "summary": "GT Biopharma Inc (GTBP) currently holds a valuation score of 6.85, placing it 284th out of 387 companies in the Biotechnology & Medical Research industry. Its P/E ratio is -0.07, indicating a significant deviation from both its recent high and low P/E values. The article notes th", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gtbp/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-25T11:10:59", "published_display": "25 Jun 2026 11:10", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GTBP PE Ratio & Valuation, Is GTBP Overvalued", "summary": "GT Biopharma Inc (GTBP) is currently in the \"Fair zone\" according to its forward PS ratio, which is considered fair compared to its five-year average. The company's current Price-to-Book (P/B) ratio is 2.54, significantly higher than its 3-year and 5-year averages, while its Forw", "url": "https://intellectia.ai/en/stock/GTBP/valuation", "source_name": "Intellectia AI", "published_at": "2026-06-22T21:11:57", "published_display": "22 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Stock - long-term cancer therapy strategy under review", "summary": "GT Biopharma (GTBP) is an immuno-oncology developer focusing on its TriKE platform for treating difficult cancers. With no new market-moving news, the company's long-term strategy, clinical milestones, and financing needs for its clinical-stage pipeline are under investor scrutin", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/gt-biopharma-stock-long-term-cancer-therapy-strategy-under-review/69592330", "source_name": "AD HOC NEWS", "published_at": "2026-06-20T18:09:27", "published_display": "20 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Inc (GTBP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article provides a revenue breakdown for GT Biopharma Inc (GTBP), noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It briefly shows the stock's performance and market capitalization bu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gtbp/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T20:39:22", "published_display": "18 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Inc (GTBP) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of GT Biopharma Inc (GTBP), detailing its price momentum score, current trading range between support and resistance levels, and signals from various technical indicators. It highlights a \"Buy\" signal based on moving averages and other i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gtbp/technical", "source_name": "TradingKey", "published_at": "2026-06-18T07:41:07", "published_display": "18 Jun 2026 07:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Inc (GTBP) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides a detailed breakdown of GT Biopharma Inc.'s (GTBP) shareholder structure, including major individual and institutional holders, and a categorized analysis of shareholder types. It also presents historical institutional shareholding data and recent shareholde", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gtbp/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T06:09:48", "published_display": "18 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Inc (GTBP) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for GT Biopharma Inc (GTBP), highlighting its current earnings forecast score of 8.00 and an average analyst price target of $8.00. Based on one analyst's rating, the stock currently holds a \"Buy\" trend. The report also includes past and", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gtbp/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T23:09:32", "published_display": "17 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Inc (GTBP) Institutional Confidence", "summary": "This article provides an overview of institutional confidence in GT Biopharma Inc (GTBP), detailing shareholdings and changes for key institutional investors. As of June 17, 2026, the company's institutional confidence score was 3.00, with notable increases in holdings by Bristol", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gtbp/sentiment", "source_name": "TradingKey", "published_at": "2026-06-16T19:09:48", "published_display": "16 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Inc (GTBP) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of GT Biopharma Inc (GTBP), reporting its current financial score as 7.52, ranking it 111 out of 388 in the Biotechnology & Medical Research industry. It notes the company's robust financial status but low operating efficiency. Key finan", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gtbp/financial-health", "source_name": "TradingKey", "published_at": "2026-06-16T07:09:32", "published_display": "16 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma, Inc. Announces Amendment to Bylaws in June 2026 SEC Form 8-K Filing", "summary": "GT Biopharma, Inc. recently filed an 8-K announcing an amendment to its bylaws, reducing the quorum requirement for shareholder meetings from a majority to one-third of outstanding shares. This change, effective June 8, 2026, aims to facilitate corporate actions due to difficulti", "url": "https://www.minichart.com.sg/2026/06/13/gt-biopharma-inc-announces-amendment-to-bylaws-in-june-2026-sec-form-8-k-filing/", "source_name": "Minichart", "published_at": "2026-06-13T13:09:39", "published_display": "13 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma (NASDAQ: GTBP) lowers meeting quorum to one-third", "summary": "GT Biopharma (NASDAQ: GTBP) has amended its bylaws to reduce the shareholder meeting quorum requirement from a majority to one-third of outstanding voting shares. This change, effective June 8, 2026, aims to make it easier for the company to achieve a quorum and conduct sharehold", "url": "https://www.stocktitan.net/sec-filings/GTBP/8-k-gt-biopharma-inc-reports-material-event-5d13046f49bc.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:08:40", "published_display": "12 Jun 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma stock (US36254L1098): FDA green light for new TriKE program puts focus on pipeline", "summary": "GT Biopharma received FDA clearance for its new IND for the GTB-5550 TriKE program, targeting B7-H3 in solid tumors. This development expands its immuno-oncology pipeline and draws attention from speculative biotech investors. As a clinical-stage micro-cap company, GT Biopharma's", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/gt-biopharma-stock-us36254l1098-fda-green-light-for-new-trike-program/69509543", "source_name": "AD HOC NEWS", "published_at": "2026-06-09T17:23:09", "published_display": "09 Jun 2026 17:23", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet", "summary": "GT Biopharma (Nasdaq: GTBP), an immuno-oncology company, has advanced three TriKE candidates into human trials, including a recent expansion into solid tumors, yet its market valuation remains modest compared to peers. The company's proprietary TriKE platform utilizes natural kil", "url": "https://www.manilatimes.net/2026/06/08/tmt-newswire/globenewswire/three-cancer-drugs-have-reached-the-clinic-inside-gt-biopharmas-trike-bet/2360843/amp", "source_name": "The Manila Times", "published_at": "2026-06-09T03:39:46", "published_display": "09 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company", "summary": "GT Biopharma, Inc. (NASDAQ: GTBP), a company with a valuation often under $20 million, has advanced its third drug, GTB-5550, into Phase 1 clinical trials for solid tumors. This milestone reflects the company's progress in leveraging its TriKE\u00ae platform beyond blood cancers, repr", "url": "https://www.sahmcapital.com/news/content/a-third-cancer-drug-just-entered-the-clinic-at-an-under-20-million-company-2026-06-02", "source_name": "Sahm", "published_at": "2026-06-03T01:39:10", "published_display": "03 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout", "summary": "GT Biopharma (NASDAQ: GTBP) announced that its integration of AI-based technologies is significantly enhancing drug discovery productivity and pipeline development. The company anticipates these AI initiatives will accelerate the advancement of new development candidates into pre", "url": "https://www.sahmcapital.com/news/content/exclusive-gt-biopharma-sees-faster-discovery-productivity-following-ai-technology-rollout-2026-06-01", "source_name": "Sahm", "published_at": "2026-06-02T01:39:10", "published_display": "02 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/gt-biopharma-provides-pipeline-discovery-120000626.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T12:00:00+00:00", "published_display": "01 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Provides Update on Pipeline Discovery", "summary": "GT Biopharma announced updates on its AI-based technological initiatives, which are accelerating the discovery and engineering of tumor-targeting engagers and multi-domain proteins. These efforts are expected to lead to new development candidates entering pre-IND development in 2", "url": "https://www.globenewswire.com/news-release/2026/06/01/3304310/0/en/gt-biopharma-provides-update-on-pipeline-discovery-activities-from-newly-implemented-ai-based-technological-initiatives.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T12:09:37", "published_display": "01 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Inc. (GTBP) Falls Over 10% as Biotech Sentiment Weakens - Ichimoku Kumo Twist", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOY19uR1dzUWFmQWo3TUUydXd6Y0ZtUzh1eTNKX3dLQ1FhbUNUNXFRYWNXZ0ZyOHN5Rk9mZWR5MW9CaVhiWFRFYjhSTGpzemlYZ3JfbjBhYzZlTVpaRk5OQUZmYzRXdEQ2M0o2VW52Nm01WWhmbHhzcXJUWk9mQVZWWDZteFdiYUg2T0VmYWdIMl84NWlnUjJpbTNfSEpycmh0VUVsczhWRWhNdw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/gt-biopharma-reports-first-quarter-120000688.html", "source_name": "GlobeNewswire", "published_at": "2026-05-15T12:00:00+00:00", "published_display": "15 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/gt-biopharma-announces-first-patient-123000954.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T12:30:00+00:00", "published_display": "14 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/exclusive-gt-biopharma-begins-testing-121607778.html", "source_name": "Benzinga", "published_at": "2026-05-14T12:16:07+00:00", "published_display": "14 May 2026 12:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "GTBP | GT Biopharma Inc. Common Insider Trading", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFBlZE9vQ1ItSktqV2pOdHVkcEVzX2diUnFQMGxZc0NwZEpTa0FoeEJKSHE0UUFjTHZlQXo1RVU5MVNwcE4zcVpLenRvTDBSRFRvRE1JWUpVckNxcnM5?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-17T14:33:50+00:00", "published_display": "17 Apr 2026 14:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPYV9BQy1DMUNQWVRfWE1yTG9fY0p2UVpBc3pFWk1tRUxrUlNuaDhSVVZCTXBRN0VRYVh5ZGozRGlLT1RJa0p2dlJub0ZJWi1YSTd2NzVFdzdYV2NzV0JwQ3B2c2pBYTNyOHNnX1BZVFl0cE9WdnoxSENPSGswRUFKMjVB?oc=5", "source_name": "Market source", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy GT Biopharma (GTBP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE9BR1V4X1k5MVhybmtlS2k2Rnh2Zy1ZR2xZb0NLREgyYTc4QmFzUGd5NDZsa0JET0psd0NGVG01dENROExSbkdSZEptUjJVVVg0U3NieGVFWUFZMXdkWHJDRzF6Nmlvb1NsTTVKTw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxQZGN3Ny1KYUdUbjRobUdSUW50bUFSVjk0RXpPSDdwMlZpblN6MlQ1RE9HdzFVSWQycW1GSlphOEs0Tjc2WlRLQWV6ZEQ0a1hHS0ozR01ZOFBjbGR5UGx4NUhlTXVQZ1FRbVVDUUtSWGdHUzZlMFFLTFFULWszX2lZLWpn?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Reports Full Year 2025 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPcGpUWkx6RDl4UzNrT3J5Z2NjbUZ0bU5ydXI3UjZnR0dPMXRXa0o2RHNrUGpSZjVjRXVEVG8xbVBBSmZUX2xEenQwYUZGbkl6S0I3dnh3MWFiSElrNE1xQ0VSNXVZZmhaOWdTMWlzSGgtaUtVX1hpdVBUUE0zdWp1V0x3?oc=5", "source_name": "Market source", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTFBvU0ctOFg0RHVoa2Q4LXV1SGtfU0phLU5UTDh0VXRnWEtVS1JibjJ4UWxteVVvQ0xiZURXbUJqTnI4YjhxZWQ0Wk9POW5wR2JTWkxPbXgtVGthekNIejNKb3Z3VnQ4UU04c2owbXZRUTE5M1dham5ZU2JSdFo0V0U?oc=5", "source_name": "Market source", "published_at": "2025-11-19T08:00:00+00:00", "published_display": "19 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Stock Logs Best Session In Over 9 Months On Promising Cancer Trial Data; Retail Eyes Double-Digit Rally", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxQMHhLSFk3SkVuVnBnd2lvRXRUMl9BaHFQTGhRVXNIRm5FUmVkcFpGLVItcXNCeU5sdW15RmNJaFlnME44NWlWdUNvMTNfUWYyVV9NWUNCM1pOZFotejRYd2xpQk8xbkF0MUZ1YmRQQWFCZVl0NmNmN3pYWFdLUG14QkREdlFwREtzcTBWaHpOeWpoVDY5aXZURjQyMEF4SUF4S1pUVHJJa0dGaUlDLVJjb0pfVHNDdUFVaTk4OFVwc0NfVk5YX0NLWmtkVG9hMG5aNWtkbi02dTBHZUNiYjMzWk1B?oc=5", "source_name": "Stocktwits", "published_at": "2025-10-08T07:00:00+00:00", "published_display": "08 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EXCLUSIVE: GT Biopharma Reports Progresses Phase 1 Trial Of Lead Drug Candidate For Blood Cancers", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPcm5NWFVwZnBhaVFPZ202LWpSS1Z4U1hwSHpXX0F4OFdpQjBjeDZSTUlPZGtuMUQ0SDZTdE55M0otTGxwSFZsNVFoZUI3eFQ5SlRyV216ejEtd21sQTlFbmV1ODNGbV9xSzRnOEJob0g3d3NMNmV5aURXSEt0TWtJVHlHa1dTUXhBNmJJTWRtWEw?oc=5", "source_name": "Market source", "published_at": "2025-10-08T07:00:00+00:00", "published_display": "08 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Retail Chatter Soars Most Among Biotechs After Financing Strategy Tweak", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQZ3BaS3ZhNjA1NnVacmVsMjFnQnlxYmk1cUplTnJjb2dfcUdVWVktN2JTdERicXJ2emsyTVliQTNOUlBDaUp1Q1hLU2UxM3gtVzlSZFdBYXdZQXk1TEg0d3ZaempDQ2FpTXVaam5FZUU3eUpQcVlrNDVHOUZ5ZTM5NWNYc0pDdnFhcENQNUtoVGJwWHdYSkkwUWFTQkh1M18xMjExUHB5WXZOSEVmNURfaWc3V2c3RTMwbE5ka19aVzgwZw?oc=5", "source_name": "Stocktwits", "published_at": "2025-02-26T02:14:42+00:00", "published_display": "26 Feb 2025 02:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma faces Nasdaq delisting over equity shortfall", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQWHFoN2gzZDNqR0c2dmpOdHFxd1VsRWNPMkpsaXV3Z3k1NVJQTjVKcXBESTdjeDgyOFZCaFA3eEhzLW95VUlocEtod1VKWW1TRUFST2NuSWlkT18wQkN0MTNsS201eEM3MTgza2ZTS3M4Zlg4cENJRGpYczR2MEY0N1NxRkp3b0JjY0tsY2R3a0ZUYnRhTVRMWGF0cWl0Qk51WmZrMW5CSUVpQmdITmxTak1OUQ?oc=5", "source_name": "Investing.com", "published_at": "2024-11-27T08:00:00+00:00", "published_display": "27 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is GT Biopharma (GTBP) Stock Up 143% Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxPZFptMEplRzQtUEw1NE1UN19Da0d3MXlicGNrRndocXhxcDlnM1lNZXVxX01fOHlJM0M5RnppMGozMURmR2U5Z1NKNGFzejhhc29aWm8yeGlJTHF0YVVrdTM2cDF4RVpicUt0a0E3czMwVXYyd0N3MFhtMUJOM0lGS3pCdXI?oc=5", "source_name": "InvestorPlace", "published_at": "2024-05-20T07:00:00+00:00", "published_display": "20 May 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for GT Biopharma (GTBP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE5tT19CWkZwcEl1Mm1fWktqdmRneGRMODBmb2hwVi1wY0xxeF9iNzlGWHlXMnRWVG0ta2FOSDBJTU8tMXZJSjJtenp4VU9acHBtWjhoT250eUotU3hwU2w0OGpYSUkyanVQZEdqUnF4QUpfX2VSLUR2Qw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2023-03-03T06:05:30+00:00", "published_display": "03 Mar 2023 06:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GTBP Stock Price and Chart \u2014 NASDAQ:GTBP", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1WLTNOSlBlYkdmbjNBbllranpUTmZYWUJ6UURjbE9ManZPNWljb3JrSWtsQUlxX0NVc1BzMWktT244eEtCZnNaNWl3MldoUFRnSUNjbTZoSVpxNmE5?oc=5", "source_name": "TradingView", "published_at": "2021-04-09T07:00:00+00:00", "published_display": "09 Apr 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gt Biopharma Stock Price Forecast. Should You Buy GTBP?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE52aU9QVFhRREp2NXRQOEZkRlFyemtEVktzcGsyZVZ5UV9PQmxaSmVaaWtmWE52blZKcUxxSVRtQ3FuTmtMOE4xcg?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-01T12:13:32+00:00", "published_display": "01 Dec 2020 12:13", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma (GTBP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTE9DaWhMQU41R3U5X0d5RDRqUXFjS0FJLXkzWGZmdGJKbkhBNHlWT3o5OE5DeFd0ZEZxbWNNcU5ncFJNT1Zad2ZKYktXZGdwdTA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2017-11-09T23:17:04+00:00", "published_display": "09 Nov 2017 23:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "GT Biopharma (GTBP) Revenue Breakdown - Main Composition", "summary": "The article \"GT Biopharma (GTBP) Revenue Breakdown - Main Composition\" is a placeholder document that suggests it's intended to detail the revenue composition of GT Biopharma. However, it currently contains no substantive content, indicating it is an empty or unwritten document.", "url": "https://www.moomoo.com/stock/GTBP-US/financials-revenue?chain_id=Name1K9-3FXPhg.1kvvik0&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A64,%22f%22%3A%22www.moomoo.com%2Fcommunity%2Fprofile%2F152378380%22%7D", "source_name": "Moomoo", "published_at": "2026-07-07T03:39:29", "published_display": "07 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma (GTBP) plans reverse stock split and larger 2022 incentive plan", "summary": "GT Biopharma (GTBP) is proposing a reverse stock split, ranging from 1-for-10 to 1-for-30, along with a reduction in authorized common and preferred shares, to regain compliance with Nasdaq's minimum bid price requirement. The company is also seeking stockholder approval to incre", "url": "https://www.stocktitan.net/sec-filings/GTBP/def-14a-gt-biopharma-inc-definitive-proxy-statement-924a06788fca.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:39:40", "published_display": "02 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of GT Biopharma, Inc. \u2013 NASDAQ:GTBP", "summary": "This article provides an overview of the Enterprise Value to EBITDA forward for GT Biopharma, Inc. (NASDAQ: GTBP). It lists the company's stock market information and indicates that no trades have occurred, with the market appearing closed. The content is primarily a data placeho", "url": "https://www.tradingview.com/symbols/NASDAQ-GTBP/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T13:14:05", "published_display": "01 Jul 2026 13:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of GT Biopharma Inc \u2013 MUN:OXIA", "summary": "This article provides financial information for GT Biopharma Inc (MUN:OXIA) on TradingView, specifically focusing on the enterprise value to EBITDA forward metric. The content, while primarily navigational and descriptive of the TradingView platform, indicates that the market was", "url": "https://www.tradingview.com/symbols/MUN-OXIA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T04:39:16", "published_display": "30 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of GT Biopharma Inc \u2013 FWB:OXIA", "summary": "This article provides financial data for GT Biopharma Inc (FWB:OXIA) on the Frankfurt Stock Exchange. It specifically highlights the \"Price to book forward\" metric, displayed within a seemingly data-driven interface provided by TradingView. The page indicates that the market is c", "url": "https://www.tradingview.com/symbols/FWB-OXIA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T03:10:11", "published_display": "29 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of GT Biopharma Inc \u2013 FWB:OXIA", "summary": "This article focuses on the \"Enterprise value to revenue forward\" metric for GT Biopharma Inc (FWB:OXIA) on the Frankfurt Stock Exchange, as presented on TradingView. It appears to be a financial data point without further analysis or detailed content presented in the provided te", "url": "https://www.tradingview.com/symbols/FWB-OXIA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T20:40:31", "published_display": "28 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of GT Biopharma, Inc. \u2013 NASDAQ:GTBP", "summary": "This article provides financial data for GT Biopharma, Inc. (NASDAQ: GTBP), specifically focusing on its enterprise value to EBIT forward. It indicates that the market is currently closed, and no trades have occurred for the stock.", "url": "https://www.tradingview.com/symbols/NASDAQ-GTBP/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T18:40:31", "published_display": "28 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Inc Actuals & Estimates (SWB:OXIA)", "summary": "This article provides an overview of GT Biopharma Inc (SWB:OXIA) financials and analyst estimates. It highlights key financial data such as earnings per share and revenue, upcoming earnings dates, and analyst price targets. The company's last reported earnings were -0.10 EUR per ", "url": "https://www.tradingview.com/symbols/SWB-OXIA/forecast-actuals-and-estimates/?category=income_statement", "source_name": "TradingView", "published_at": "2026-06-27T07:40:08", "published_display": "27 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Inc (GTBP) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for GT Biopharma Inc (GTBP), noting its current risk assessment score of 1.27 and ranking within the Biotechnology & Medical Research industry. It details the company's beta value of 0.79, indicating it tends to underperform during upward m", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gtbp/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-27T05:11:21", "published_display": "27 Jun 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Inc Actuals & Estimates (NASDAQ:GTBP)", "summary": "This article provides an overview of GT Biopharma, Inc. (NASDAQ: GTBP) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the stock's recent decline, an analyst price target of USD 3.00, and upcoming earnings report sc", "url": "https://www.tradingview.com/symbols/NASDAQ-GTBP/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T16:10:59", "published_display": "25 Jun 2026 16:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Inc (GTBP) Valuation: PE, PB & Fair Value Analysis", "summary": "GT Biopharma Inc (GTBP) currently holds a valuation score of 6.85, placing it 284th out of 387 companies in the Biotechnology & Medical Research industry. Its P/E ratio is -0.07, indicating a significant deviation from both its recent high and low P/E values. The article notes th", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gtbp/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-25T11:10:59", "published_display": "25 Jun 2026 11:10", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GTBP PE Ratio & Valuation, Is GTBP Overvalued", "summary": "GT Biopharma Inc (GTBP) is currently in the \"Fair zone\" according to its forward PS ratio, which is considered fair compared to its five-year average. The company's current Price-to-Book (P/B) ratio is 2.54, significantly higher than its 3-year and 5-year averages, while its Forw", "url": "https://intellectia.ai/en/stock/GTBP/valuation", "source_name": "Intellectia AI", "published_at": "2026-06-22T21:11:57", "published_display": "22 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Stock - long-term cancer therapy strategy under review", "summary": "GT Biopharma (GTBP) is an immuno-oncology developer focusing on its TriKE platform for treating difficult cancers. With no new market-moving news, the company's long-term strategy, clinical milestones, and financing needs for its clinical-stage pipeline are under investor scrutin", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/gt-biopharma-stock-long-term-cancer-therapy-strategy-under-review/69592330", "source_name": "AD HOC NEWS", "published_at": "2026-06-20T18:09:27", "published_display": "20 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Inc (GTBP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article provides a revenue breakdown for GT Biopharma Inc (GTBP), noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It briefly shows the stock's performance and market capitalization bu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gtbp/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T20:39:22", "published_display": "18 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Inc (GTBP) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of GT Biopharma Inc (GTBP), detailing its price momentum score, current trading range between support and resistance levels, and signals from various technical indicators. It highlights a \"Buy\" signal based on moving averages and other i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gtbp/technical", "source_name": "TradingKey", "published_at": "2026-06-18T07:41:07", "published_display": "18 Jun 2026 07:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Inc (GTBP) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides a detailed breakdown of GT Biopharma Inc.'s (GTBP) shareholder structure, including major individual and institutional holders, and a categorized analysis of shareholder types. It also presents historical institutional shareholding data and recent shareholde", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gtbp/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T06:09:48", "published_display": "18 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Inc (GTBP) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for GT Biopharma Inc (GTBP), highlighting its current earnings forecast score of 8.00 and an average analyst price target of $8.00. Based on one analyst's rating, the stock currently holds a \"Buy\" trend. The report also includes past and", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gtbp/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T23:09:32", "published_display": "17 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Inc (GTBP) Institutional Confidence", "summary": "This article provides an overview of institutional confidence in GT Biopharma Inc (GTBP), detailing shareholdings and changes for key institutional investors. As of June 17, 2026, the company's institutional confidence score was 3.00, with notable increases in holdings by Bristol", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gtbp/sentiment", "source_name": "TradingKey", "published_at": "2026-06-16T19:09:48", "published_display": "16 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Inc (GTBP) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of GT Biopharma Inc (GTBP), reporting its current financial score as 7.52, ranking it 111 out of 388 in the Biotechnology & Medical Research industry. It notes the company's robust financial status but low operating efficiency. Key finan", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gtbp/financial-health", "source_name": "TradingKey", "published_at": "2026-06-16T07:09:32", "published_display": "16 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma, Inc. Announces Amendment to Bylaws in June 2026 SEC Form 8-K Filing", "summary": "GT Biopharma, Inc. recently filed an 8-K announcing an amendment to its bylaws, reducing the quorum requirement for shareholder meetings from a majority to one-third of outstanding shares. This change, effective June 8, 2026, aims to facilitate corporate actions due to difficulti", "url": "https://www.minichart.com.sg/2026/06/13/gt-biopharma-inc-announces-amendment-to-bylaws-in-june-2026-sec-form-8-k-filing/", "source_name": "Minichart", "published_at": "2026-06-13T13:09:39", "published_display": "13 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma (NASDAQ: GTBP) lowers meeting quorum to one-third", "summary": "GT Biopharma (NASDAQ: GTBP) has amended its bylaws to reduce the shareholder meeting quorum requirement from a majority to one-third of outstanding voting shares. This change, effective June 8, 2026, aims to make it easier for the company to achieve a quorum and conduct sharehold", "url": "https://www.stocktitan.net/sec-filings/GTBP/8-k-gt-biopharma-inc-reports-material-event-5d13046f49bc.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:08:40", "published_display": "12 Jun 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma stock (US36254L1098): FDA green light for new TriKE program puts focus on pipeline", "summary": "GT Biopharma received FDA clearance for its new IND for the GTB-5550 TriKE program, targeting B7-H3 in solid tumors. This development expands its immuno-oncology pipeline and draws attention from speculative biotech investors. As a clinical-stage micro-cap company, GT Biopharma's", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/gt-biopharma-stock-us36254l1098-fda-green-light-for-new-trike-program/69509543", "source_name": "AD HOC NEWS", "published_at": "2026-06-09T17:23:09", "published_display": "09 Jun 2026 17:23", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet", "summary": "GT Biopharma (Nasdaq: GTBP), an immuno-oncology company, has advanced three TriKE candidates into human trials, including a recent expansion into solid tumors, yet its market valuation remains modest compared to peers. The company's proprietary TriKE platform utilizes natural kil", "url": "https://www.manilatimes.net/2026/06/08/tmt-newswire/globenewswire/three-cancer-drugs-have-reached-the-clinic-inside-gt-biopharmas-trike-bet/2360843/amp", "source_name": "The Manila Times", "published_at": "2026-06-09T03:39:46", "published_display": "09 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company", "summary": "GT Biopharma, Inc. (NASDAQ: GTBP), a company with a valuation often under $20 million, has advanced its third drug, GTB-5550, into Phase 1 clinical trials for solid tumors. This milestone reflects the company's progress in leveraging its TriKE\u00ae platform beyond blood cancers, repr", "url": "https://www.sahmcapital.com/news/content/a-third-cancer-drug-just-entered-the-clinic-at-an-under-20-million-company-2026-06-02", "source_name": "Sahm", "published_at": "2026-06-03T01:39:10", "published_display": "03 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout", "summary": "GT Biopharma (NASDAQ: GTBP) announced that its integration of AI-based technologies is significantly enhancing drug discovery productivity and pipeline development. The company anticipates these AI initiatives will accelerate the advancement of new development candidates into pre", "url": "https://www.sahmcapital.com/news/content/exclusive-gt-biopharma-sees-faster-discovery-productivity-following-ai-technology-rollout-2026-06-01", "source_name": "Sahm", "published_at": "2026-06-02T01:39:10", "published_display": "02 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/gt-biopharma-provides-pipeline-discovery-120000626.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T12:00:00+00:00", "published_display": "01 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Provides Update on Pipeline Discovery", "summary": "GT Biopharma announced updates on its AI-based technological initiatives, which are accelerating the discovery and engineering of tumor-targeting engagers and multi-domain proteins. These efforts are expected to lead to new development candidates entering pre-IND development in 2", "url": "https://www.globenewswire.com/news-release/2026/06/01/3304310/0/en/gt-biopharma-provides-update-on-pipeline-discovery-activities-from-newly-implemented-ai-based-technological-initiatives.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T12:09:37", "published_display": "01 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Inc. (GTBP) Falls Over 10% as Biotech Sentiment Weakens - Ichimoku Kumo Twist", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOY19uR1dzUWFmQWo3TUUydXd6Y0ZtUzh1eTNKX3dLQ1FhbUNUNXFRYWNXZ0ZyOHN5Rk9mZWR5MW9CaVhiWFRFYjhSTGpzemlYZ3JfbjBhYzZlTVpaRk5OQUZmYzRXdEQ2M0o2VW52Nm01WWhmbHhzcXJUWk9mQVZWWDZteFdiYUg2T0VmYWdIMl84NWlnUjJpbTNfSEpycmh0VUVsczhWRWhNdw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/gt-biopharma-reports-first-quarter-120000688.html", "source_name": "GlobeNewswire", "published_at": "2026-05-15T12:00:00+00:00", "published_display": "15 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/gt-biopharma-announces-first-patient-123000954.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T12:30:00+00:00", "published_display": "14 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/exclusive-gt-biopharma-begins-testing-121607778.html", "source_name": "Benzinga", "published_at": "2026-05-14T12:16:07+00:00", "published_display": "14 May 2026 12:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GTBP | GT Biopharma Inc. Common Insider Trading", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFBlZE9vQ1ItSktqV2pOdHVkcEVzX2diUnFQMGxZc0NwZEpTa0FoeEJKSHE0UUFjTHZlQXo1RVU5MVNwcE4zcVpLenRvTDBSRFRvRE1JWUpVckNxcnM5?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-17T14:33:50+00:00", "published_display": "17 Apr 2026 14:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPYV9BQy1DMUNQWVRfWE1yTG9fY0p2UVpBc3pFWk1tRUxrUlNuaDhSVVZCTXBRN0VRYVh5ZGozRGlLT1RJa0p2dlJub0ZJWi1YSTd2NzVFdzdYV2NzV0JwQ3B2c2pBYTNyOHNnX1BZVFl0cE9WdnoxSENPSGswRUFKMjVB?oc=5", "source_name": "Market source", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy GT Biopharma (GTBP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE9BR1V4X1k5MVhybmtlS2k2Rnh2Zy1ZR2xZb0NLREgyYTc4QmFzUGd5NDZsa0JET0psd0NGVG01dENROExSbkdSZEptUjJVVVg0U3NieGVFWUFZMXdkWHJDRzF6Nmlvb1NsTTVKTw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxQZGN3Ny1KYUdUbjRobUdSUW50bUFSVjk0RXpPSDdwMlZpblN6MlQ1RE9HdzFVSWQycW1GSlphOEs0Tjc2WlRLQWV6ZEQ0a1hHS0ozR01ZOFBjbGR5UGx4NUhlTXVQZ1FRbVVDUUtSWGdHUzZlMFFLTFFULWszX2lZLWpn?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Reports Full Year 2025 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPcGpUWkx6RDl4UzNrT3J5Z2NjbUZ0bU5ydXI3UjZnR0dPMXRXa0o2RHNrUGpSZjVjRXVEVG8xbVBBSmZUX2xEenQwYUZGbkl6S0I3dnh3MWFiSElrNE1xQ0VSNXVZZmhaOWdTMWlzSGgtaUtVX1hpdVBUUE0zdWp1V0x3?oc=5", "source_name": "Market source", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTFBvU0ctOFg0RHVoa2Q4LXV1SGtfU0phLU5UTDh0VXRnWEtVS1JibjJ4UWxteVVvQ0xiZURXbUJqTnI4YjhxZWQ0Wk9POW5wR2JTWkxPbXgtVGthekNIejNKb3Z3VnQ4UU04c2owbXZRUTE5M1dham5ZU2JSdFo0V0U?oc=5", "source_name": "Market source", "published_at": "2025-11-19T08:00:00+00:00", "published_display": "19 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Stock Logs Best Session In Over 9 Months On Promising Cancer Trial Data; Retail Eyes Double-Digit Rally", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxQMHhLSFk3SkVuVnBnd2lvRXRUMl9BaHFQTGhRVXNIRm5FUmVkcFpGLVItcXNCeU5sdW15RmNJaFlnME44NWlWdUNvMTNfUWYyVV9NWUNCM1pOZFotejRYd2xpQk8xbkF0MUZ1YmRQQWFCZVl0NmNmN3pYWFdLUG14QkREdlFwREtzcTBWaHpOeWpoVDY5aXZURjQyMEF4SUF4S1pUVHJJa0dGaUlDLVJjb0pfVHNDdUFVaTk4OFVwc0NfVk5YX0NLWmtkVG9hMG5aNWtkbi02dTBHZUNiYjMzWk1B?oc=5", "source_name": "Stocktwits", "published_at": "2025-10-08T07:00:00+00:00", "published_display": "08 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EXCLUSIVE: GT Biopharma Reports Progresses Phase 1 Trial Of Lead Drug Candidate For Blood Cancers", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPcm5NWFVwZnBhaVFPZ202LWpSS1Z4U1hwSHpXX0F4OFdpQjBjeDZSTUlPZGtuMUQ0SDZTdE55M0otTGxwSFZsNVFoZUI3eFQ5SlRyV216ejEtd21sQTlFbmV1ODNGbV9xSzRnOEJob0g3d3NMNmV5aURXSEt0TWtJVHlHa1dTUXhBNmJJTWRtWEw?oc=5", "source_name": "Market source", "published_at": "2025-10-08T07:00:00+00:00", "published_display": "08 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma Retail Chatter Soars Most Among Biotechs After Financing Strategy Tweak", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQZ3BaS3ZhNjA1NnVacmVsMjFnQnlxYmk1cUplTnJjb2dfcUdVWVktN2JTdERicXJ2emsyTVliQTNOUlBDaUp1Q1hLU2UxM3gtVzlSZFdBYXdZQXk1TEg0d3ZaempDQ2FpTXVaam5FZUU3eUpQcVlrNDVHOUZ5ZTM5NWNYc0pDdnFhcENQNUtoVGJwWHdYSkkwUWFTQkh1M18xMjExUHB5WXZOSEVmNURfaWc3V2c3RTMwbE5ka19aVzgwZw?oc=5", "source_name": "Stocktwits", "published_at": "2025-02-26T02:14:42+00:00", "published_display": "26 Feb 2025 02:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma faces Nasdaq delisting over equity shortfall", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQWHFoN2gzZDNqR0c2dmpOdHFxd1VsRWNPMkpsaXV3Z3k1NVJQTjVKcXBESTdjeDgyOFZCaFA3eEhzLW95VUlocEtod1VKWW1TRUFST2NuSWlkT18wQkN0MTNsS201eEM3MTgza2ZTS3M4Zlg4cENJRGpYczR2MEY0N1NxRkp3b0JjY0tsY2R3a0ZUYnRhTVRMWGF0cWl0Qk51WmZrMW5CSUVpQmdITmxTak1OUQ?oc=5", "source_name": "Investing.com", "published_at": "2024-11-27T08:00:00+00:00", "published_display": "27 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is GT Biopharma (GTBP) Stock Up 143% Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxPZFptMEplRzQtUEw1NE1UN19Da0d3MXlicGNrRndocXhxcDlnM1lNZXVxX01fOHlJM0M5RnppMGozMURmR2U5Z1NKNGFzejhhc29aWm8yeGlJTHF0YVVrdTM2cDF4RVpicUt0a0E3czMwVXYyd0N3MFhtMUJOM0lGS3pCdXI?oc=5", "source_name": "InvestorPlace", "published_at": "2024-05-20T07:00:00+00:00", "published_display": "20 May 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for GT Biopharma (GTBP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE5tT19CWkZwcEl1Mm1fWktqdmRneGRMODBmb2hwVi1wY0xxeF9iNzlGWHlXMnRWVG0ta2FOSDBJTU8tMXZJSjJtenp4VU9acHBtWjhoT250eUotU3hwU2w0OGpYSUkyanVQZEdqUnF4QUpfX2VSLUR2Qw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2023-03-03T06:05:30+00:00", "published_display": "03 Mar 2023 06:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GTBP Stock Price and Chart \u2014 NASDAQ:GTBP", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1WLTNOSlBlYkdmbjNBbllranpUTmZYWUJ6UURjbE9ManZPNWljb3JrSWtsQUlxX0NVc1BzMWktT244eEtCZnNaNWl3MldoUFRnSUNjbTZoSVpxNmE5?oc=5", "source_name": "TradingView", "published_at": "2021-04-09T07:00:00+00:00", "published_display": "09 Apr 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gt Biopharma Stock Price Forecast. Should You Buy GTBP?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE52aU9QVFhRREp2NXRQOEZkRlFyemtEVktzcGsyZVZ5UV9PQmxaSmVaaWtmWE52blZKcUxxSVRtQ3FuTmtMOE4xcg?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-01T12:13:32+00:00", "published_display": "01 Dec 2020 12:13", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GT Biopharma (GTBP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTE9DaWhMQU41R3U5X0d5RDRqUXFjS0FJLXkzWGZmdGJKbkhBNHlWT3o5OE5DeFd0ZEZxbWNNcU5ncFJNT1Zad2ZKYktXZGdwdTA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2017-11-09T23:17:04+00:00", "published_display": "09 Nov 2017 23:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 96, "total_relevant": 55, "sentiment_summary": {"positive": 11, "negative": 4, "neutral": 40, "score": 53, "total": 55, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 18.85, "count": 33}, {"event": "earnings", "label": "Earnings", "weight": 7.56, "count": 16}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 1.45, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 11, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 0.36, "latest_week": "2026-07-17", "one_week_move": -16.3, "four_week_move": -30.8, "twelve_week_move": 13.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.185207, "market_dynamics_buy_signal": false, "relative_strength": -54.407078, "fair_value_gap": -88.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 43.6496, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-16.3% over one week, -30.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "TradingView", "count": 9}, {"label": "TradingKey", "count": 8}, {"label": "GlobeNewswire", "count": 4}, {"label": "Zacks Investment Research", "count": 3}, {"label": "Stock Titan", "count": 2}, {"label": "AD HOC NEWS", "count": 2}, {"label": "Sahm", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Earnings", "count": 16}, {"label": "Analyst action", "count": 3}, {"label": "Guidance", "count": 2}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-16.3% over one week, -30.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "GT Biopharma (GTBP) Revenue Breakdown - Main Composition"}], "updated_at": "2026-07-23T08:48:48.712781+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}